- Adults
- General population
- Community
- SARS-CoV-2
- Post-COVID-19
- Colchicine
- Antihistamines
- Rivaroxaban
Setting: Community
A research environment where studies are conducted outside of clinical or laboratory settings, focusing on real-world populations
- Adults
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Venezuelan equine encephalitis virus
- Arboviral disease
- Vector-borne disease
- Adults
- General population
- Paediatric
- Pregnant women
- Community
- Arbovirus
- Vector-borne disease
- Zika virus
- Arboviral disease
- Vector-borne disease
- Blood sample
- Urine sample
- Hair
- Saliva
- Semen
- Vaginal fluids
- Adults
- Elderly
- People at high risk of STIs
- PrEP users
- Hospital wide
- Community
- Primary care
- Chlamydia trachomatis
- Neisseria gonorrhoeae
- Syphilis
- Sexually transmitted infection
- Pharmacological intervention
- PrEP-bSTI
- Adults
- General population
- Pregnant women
- Community
- Chlamydia trachomatis
- Sexually transmitted infection
- Adults
- Elderly
- Travelers
- Community
- Telemedicine
- Arbovirus
- Chikungunya virus
- Vector-borne
- Dengue virus
- West Nile virus
- Arboviral disease
- Vector-borne disease
- Post-infectious condition
- Non pharmacological intervention
- Digital health
- Adults
- Elderly
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-infectious condition
- Adults
- Elderly
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-infectious condition
- Adults
- Elderly
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-infectious condition
- Adults
- Elderly
- Community
- Arbovirus
- Chikungunya virus
- Vector-borne
- Arboviral disease
- Vector-borne disease
- Post-infectious condition
- Adults
- General population
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- vasodilator
- Vericiguat